Breaking News

Societal CDMO Announces Corporate Restructuring

Reduces 9% of workforce in an effort to right size the organization and save $5.5 million annually.

Societal CDMO, Inc., a contract development and manufacturing organization (CDMO), is implementing a strategic restructuring plan to streamline and optimize operations.

Societal has reduced its workforce by 26 positions (9%) across all the business, effective September 20, 2023, and has eliminated nine open positions. These moves are expected to result in annualized savings of approximately $5.5 million. A significant majority of the cuts will impact the portion of the business supporting earlier-stage services, which are most acutely affected by the current financing environment.

To further support the organizational realignment, Societal has appointed Wayne Weisman, the current chairman, as executive chairman of the board of directors. Mr. Weisman, along with the support of the board, will provide more direct oversight on the implementation and execution of the corporate strategy.

“Our executive team, in collaboration with our board of directors, has executed a careful review of our current operations and resources and determined that this strategic realignment is essential at this time,” said David Enloe, chief executive officer of Societal CDMO. “Industry-wide funding challenges, which are particularly impacting early-stage drug development, dictate that we reduce our infrastructure in areas that support companies most affected by this slowdown. Taking these difficult but important steps will enable us to increase our operational efficiency, especially in areas that historically have been our greatest strengths. Additionally, this restructuring will bolster our ability to achieve our growth strategies and continue to deliver on our commitment to playing a key role in bringing important medicines to patients.

Enloe added: “We are deeply appreciative of the tireless commitment of all our team members and extend a heartfelt thank you for the essential contributions made by those that are impacted by this restructuring.”

Weisman said, “I am pleased to assume the role of executive chairman and further support our management as it navigates today’s challenging financial environment. I, as well as the other members of the Societal board of directors, have an excellent working relationship with our management team, and I appreciate the opportunity to expand our engagement on these strategic matters.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters